Investigating the Vascular Toxicity Outcomes of the Irreversible Proteasome Inhibitor Carfilzomib
Panagiotis Efentakis(Johannes Gutenberg University Mainz), Evangelos Terpos(National and Kapodistrian University of Athens)
Cited by 24
Related Papers
Hematological findings and complications of <scp>COVID</scp>‐19
|American Journal of Hematology|2020|1.7k
Elucidating Carfilzomib’s Induced Cardiotoxicity in an In Vivo Model of Aging: Prophylactic Potential of Metformin
|International Journal of Molecular Sciences|2021|16